Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours

Schoffski Patrick; Gordon Michael; Smith David C.; Kurzrock Razelle; Daud Adil; Vogelzang Nicholas J.; Lee Yihua; Scheffold Christian; Shapiro Geoffrey I.

首页> 外文期刊>European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) >Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours

【24h】

Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours

机译：Cabozantib在高级实体肿瘤患者中的II期随机停止试验试验试验试验试验试验试验试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: Cabozantinib is an inhibitor of tyrosine kinases, including MET, vascular endothelial growth factor receptor, AXL and RET. This multi-cohort phase II randomised discontinuation trial explored anticancer activity of cabozantinib in nine tumour types.

机译：背景：Cabozantinib是酪氨酸激酶的抑制剂，包括满足，血管内皮生长因子受体，AXL和RET。这种多队队第II期随机停药试验试验试验试验试验试验试验试验试验试验试验试验试验试验试验患者在九种肿瘤类型中的Cabozantib抗癌活性。

著录项

来源
《European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)》 |2017年第2017期|共9页
作者
Schoffski Patrick; Gordon Michael; Smith David C.; Kurzrock Razelle; Daud Adil; Vogelzang Nicholas J.; Lee Yihua; Scheffold Christian; Shapiro Geoffrey I.;
展开▼
作者单位

Univ Hosp Leuven Leuven Canc Inst Dept Gen Med Oncol Leuven Belgium;

Pinnacle Oncol Hematol Scottsdale AZ USA;

Univ Michigan Dept Internal Med Div Hematol Oncol Ann Arbor MI 48109 USA;

Univ Calif San Diego Moores Canc Ctr San Diego CA 92103 USA;

Univ Calif San Francisco Med Ctr Parnassus San Francisco CA 94143 USA;

US Oncol Res Comprehens Canc Ctr Nevada Las Vegas NV USA;

Exelixis Inc San Francisco CA USA;

Exelixis Inc San Francisco CA USA;

Dana Farber Canc Inst Dept Med Oncol Early Drug Dev Ctr Boston MA 02115 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Cabozantinib; Vascular endothelial growth factor receptor; Solid tumour; Objective response rate; Progression-free survival; Randomised discontinuation trial;

机译：Cabozantib;血管内皮生长因子受体;实体肿瘤;客观反应率;无进展生存;随机停产试验;

相似文献

外文文献
中文文献
专利

1. 来自一项艾日布林联合吉西他滨对比紫杉醇联合吉西他滨作为HER2阴性转移性乳腺癌的一线化疗的II期、多中心、随机试验的包含神经病变相关量表的生活质量结果:韩国癌症研究组试验(KCSG BR13-11) [J] . Ji-Yeon Kim, Young-Hyuck Im, Tae-Yong Kim, 癌症（英文版） . 2019,第008期
2. Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours [J] . Schoffski Patrick, Gordon Michael, Smith David C., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2017,第期

机译：Cabozantib在高级实体肿瘤患者中的II期随机停止试验试验试验试验试验试验试验试验
3. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. [J] . David C Smith, Matthew R Smith, Christopher Sweeney, Journal of Clinical Oncology . 2013,第4期

机译：卡博替尼在晚期前列腺癌患者中的应用：II期随机停用试验的结果。
4. Commentary on "Cabozantinib in patients with advanced prostate cancer: Results of a phase II randomized discontinuation trial." Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN Jr, Lin CC, Srinivas S, Sella A, SchoffskiSch?ffski P [J] . TrumpD.L. Urologic oncology . 2013,第8期

机译：关于“卡波替尼在晚期前列腺癌患者中的应用：II期随机终止试验的结果”的评论。 Smith DC，Smith MR，Sweeney C，Elfiky AA，Logothetis C，玉米PG，Vogelzang NJ，Small EJ，Harzstark AL，Gordon MS，Vaishampayan UN，Haas NB，Spira AI，Lara PN Jr，Lin CC，Srinivas S，Sella肖夫斯基·肖夫斯基P
5. A Framework for Patient Data Management and Analysis in Randomised Clinical Trials [C] . Pietro Hiram Guzzi, Tiziana Larussa, Rosarina Vallelunga, IEEE International Conference on Bioinformatics and Biomedicine . 2020

机译：随机临床试验中患者数据管理和分析的框架
6. Communication preferences, expectations of benefit, and symptom burdens among advanced cancer patients and partners during patient participation in phase I trials [D] . Hlubocky, Fay J. 2010

机译：患者参加I期试验期间，晚期癌症患者及其伴侣之间的沟通偏好，受益期望以及症状负担
7. Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour [O] . Jianrong Zhang, Yiyin Zhang, Shiyan Tang, 2018

机译：盲法独立中央评价与局部评价之间的系统偏倚：文献回顾与分析对45 688例晚期实体瘤患者进行的76项III期随机对照试验
8. Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours [O] . Patrick Schöffski, Michael Gordon, David C. Smith, 2017

机译：Cabozantinib在高级实体肿瘤患者中的II期随机停药试验试验试验试验试验试验试验试验试验

Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours

摘要

著录项

相似文献

相关主题

期刊订阅